Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 0.83 |
| ▸ | CLK2 | P49760 | 7/20 | 0.83 |
| ▸ | CLK3 | P49761 | 7/20 | 0.83 |
| ▸ | WNT1 | P04628 | 8/20 | 0.63 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.61 |
| ▸ | GSK3B | P49841 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15301354 | 0.91 | CLK3 (1.00) | DYRK1ACLK2CLK3WNT1GSK3B | |
| SCHEMBL15868960 | 0.90 | DYRK1A (0.80) | DYRK1ACLK2CLK3WNT1TGFBR1 | |
| SCHEMBL17638264 | 0.89 | CLK2 (0.77) | DYRK1ACLK2CLK3WNT1TGFBR1 | |
| SCHEMBL15862475 | 0.88 | DYRK1A (0.68) | DYRK1ACLK2CLK3WNT1TGFBR1 | |
| SCHEMBL15371225 | 0.88 | DYRK1A (0.65) | DYRK1ACLK2CLK3WNT1TGFBR1 | |
| SCHEMBL17587084 | 0.88 | DYRK1A (0.75) | DYRK1ACLK2CLK3WNT1GSK3B | |
| SCHEMBL15868982 | 0.87 | DYRK1A (0.72) | DYRK1ACLK2CLK3WNT1TGFBR1 | |
| SCHEMBL17566041 | 0.87 | WNT1 (0.82) | DYRK1ACLK2CLK3WNT1TGFBR1 | |
| SCHEMBL15869101 | 0.87 | DYRK1A (0.66) | DYRK1ACLK2CLK3WNT1TGFBR1 | |
| SCHEMBL15869100 | 0.86 | DYRK1A (0.65) | DYRK1ACLK2CLK3WNT1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-11-21 | — | — | US | disclosed |
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2014110086-A2 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 432/4885CLK2 395/4885CLK3 352/4885 |
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | DYRK1A 432/4885CLK2 395/4885CLK3 352/4885 |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 432/4885CLK2 395/4885CLK3 352/4885 |
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | DYRK1A 432/4885CLK2 395/4885CLK3 352/4885 |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | DYRK1A 432/4885CLK2 395/4885CLK3 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.